Drug intelligence / Profile preview

BE 4444

Development stage: Preclinical
Modality: Small Molecules

Overview

BE 4444 is a synthetic polyamine analogue that demonstrates antiproliferative effects in human tumor cells. It is being investigated for its capacity to inhibit tumor proliferation by modulating endogenous polyamine metabolism. This mechanism suggests its potential as an adjunct for concurrent use with radiation therapy, particularly in the treatment of advanced head and neck squamous cell carcinoma, where it aims to mitigate tumor cell proliferation during the course of therapy.

Other names: 1,19-bis(ethylamino)-5,10,15-triazanonadecane

Targets

SAT1 (Spermidine/spermine N1-acetyltransferase 1)Polyamine transporter

Beyond the preview

Go deeper on BE 4444.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BE 4444.

Explore the full profile